Targeted diagnosis and therapy enable precise tumor detection and treatment. Successful
examples for precise tumor targeting are diagnostic and therapeutic radioligands. However …

Abstract Pheochromocytomas and paragangliomas (PCCs/PGLs) are catecholamine-
producing tumors. In inoperable and metastatic cases, somatostatin type 2 receptor (SSTR2) …

There is recent in vitro and in vivo evidence that somatostatin receptor subtype 2 (sst2)
antagonists are better tools to target neuroendocrine tumors (NETs) than sst2 agonists …

Abstract Background Somatostatin receptor-2 (SSTR2) is expressed on cell surface of
neuroendocrine neoplasias; its presence is exploited for the delivery of peptide receptor …

Somatostatin (SST) receptors (SSTRs) belong to the typical 7‐transmembrane domain
family of G‐protein‐coupled receptors. Five distinct subtypes (termed SSTR1‐5) have been …

Recent studies have shown enhanced tumor targeting by novel somatostatin receptor
(SSTR) antagonists compared with clinically widely used agonists. However, these results …

The human somatostatin receptor subtype 2A (hSSTr2) is under evaluation as a reporter
gene for molecular imaging applications. Two approved somatostatin analogues are already …

Purpose: The goal of this study was to analyze the role of somatostatin receptor type 2
(SSTR2) as a molecular target for the imaging and treatment of thyroid cancer through …

Somatostatin receptor targeting of neuroendocrine tumors using radiolabeled somatostatin
agonists is today an established method to image and treat cancer patients. However, in a …

Radiolabeled sst2 and sst3 antagonists are better candidates for tumor targeting than
agonists with comparable binding characteristics (Ginj, M.; Zhang, H.; Waser, B.; Cescato …